Archive for the ‘Blood Cancer’ Category

Alcohol intake during pregnancy Raises Acute Myeloid Leukemia risk in Unborn Baby
Alcohol intake during pregnancy Raises Acute Myeloid Leukemia risk in Unborn Baby
Expectant mothers who indulge in drinking could raise risk of AML or acute myeloid leukemia in their fetuses, according to recent study finding printed in the journal ‘Cancer Epidemiology, Biomarkers & Prevention’. This study outcome provides yet another reason to the burgeoning listing of reasons for not drinking during pregnancy, the heightened perils of acute myeloid leukemia developing in children in the age group of 0-4 years was found to rise among mothers that self-cited having a single alcoholic drink in a week. The research additionally took into consideration the type of alcoholic drink being consumed. Helming the study, Dr. Paule Latino-Martel stated that advice on not drinking when pregnant would be pertinent to all forms of alcoholic drinks. The study finding showed that  [...]

May 12th, 2010 | Blood Cancer, News
Baby’s Breath could augment Leukemia Treatment Efficacy by a Million Fold
Baby’s Breath could augment Leukemia Treatment Efficacy by a Million Fold
Study researchers have uncovered a significant medical advancement which can transform leukemia treatment and be truly a life-saving endeavor. Specialists have made a discovery that white flower prevalently called as Baby’s Breath extract could augment the efficacy of cancer-combatant medications by an astounding million fold. The study investigators observed that molecules known as saponins obtained after extraction from the plant, botanically named Gypsophila Paniculata appears to breakdown cancer cell membranes. This helps in simplifying the task of antibody based medications called as immunotoxins in assaulting the malignant cells. As a consequence, immunotherapy employed for leukemia treatment involving particular forms and lymphoma is augmented in strength by more than a million times. The  [...]

May 1st, 2010 | Blood Cancer
Novel PCI-32765 Cancer Therapy Offers Optimism to Leukemia, Lymphoma Sufferers
Novel PCI-32765 Cancer Therapy Offers Optimism to Leukemia, Lymphoma Sufferers
Cancer investigators are hopeful about a new-fangled treatment for those patients inflicted with particular forms of leukemia and lymphoma. An assessment of the new-fangled medicine, PCI-32765 in its first phase clinical study is one of the thirty-five ongoing clinical trials via a joint venture between TGen’s Clinical Division (Translational Genomics Research Institute) and Virginia G. Piper Cancer Center. This alliance facilitates genomics and molecular inventions to become obtainable to patients via the first phase of the clinical trials as soon as doable. Several experts have pointed out to the excruciatingly sluggish advancement in the development of novel cancer treatments solely due to merely two to four percent of all cancer sufferers enrolling in clinical studies. This is largely  [...]

March 2nd, 2010 | Blood Cancer, News
Headway in Leukemia Vaccine Development Shows Potential
Headway in Leukemia Vaccine Development Shows Potential
Investigators from Britain have come up with a cure that could be employed for halting the disease relapsing following chemotherapy or BMT (bone marrow transplant). In the long run, it is anticipated that the drug that could activate the body’s own immune system to combat leukemia, may well be utilized for treating other cancer forms. The entrants in the study had acute myeloid leukemia or AML, the widespread type found in adults. Despite undergoing belligerent treatment, nearly half of them would generally experience the disease to recur. The thought behind cancer vaccine is not essentially preventing the disease but rather programming the body’s immune system in hunting down cancerous cells and obliterating them. The vaccine then elicits the immune system in recognising leukemia cells  [...]

February 19th, 2010 | Blood Cancer, News
Crucial Gene Identification Would Aid In Adeptly Steering Acute Lymphoblastic Leukemia Treatment
Crucial Gene Identification Would Aid In Adeptly Steering Acute Lymphoblastic Leukemia Treatment
Oncologists have detected explicit genes named partner genes which combine with another type of gene for driving a pre-dominantly terminal kind of leukemia among children. Researchers anticipate that by more accurate identification of particular partner genes would aid in better forecasting which children could gain from specific treatments. Oncologists additionally intend to employ this recent know-how for developing novel and more effectual treatments for acute lymphoblastic leukemia, the most stubborn of all the types of leukemia. The oncologists are aiming at targeting treatments to particular genes and other related factors that turn anomalous due to gene fusions. ALL is the widespread form of all the childhood cancers. Even though there has been a surge of survival rates in kids over  [...]

December 14th, 2009 | Blood Cancer
Novel Use Of Umbilical Cord Blood For Reducing Risk Of Leukemia Relapse
Novel Use Of Umbilical Cord Blood For Reducing Risk Of Leukemia Relapse
A novel leukemia research conducted in the Masonic Cancer Center, University of Minnesota reveals that those patients having acute leukemia when administered transplantation of 2 units of UCB or umbilical cord blood had extensive reduction in risk of the disease relapsing. This discovery shows promise in changing the present medical practice of employing a single UCB unit for treating patients having a high risk of relapse of leukemia and other kinds of cancers affecting the blood and bone marrow. Michael Verneris, M.D., and John Wagner, M.D., who have dedicated themselves to the research and treatment of infants having cancer, helmed the research team on this innovative study. The outcomes of this study are printed in the present edition of the medical journal ‘Blood’. This study was backed  [...]

November 24th, 2009 | Blood Cancer
Hairy Cell Leukemia Treatment
Hairy Cell Leukemia Treatment
Treatment and Drugs Treatment is not always required for individuals having hairy cell leukemia as this type of cancer has a slow progression rate and at times does not advance at all, some individuals would rather follow the wait and watch policy and prefer getting treated solely after they start becoming symptomatic. The major populace of individuals having hairy cell leukemia would ultimately require treatment. Though one might be keen to free one’s body of any malignancy following diagnosis with hairy cell leukemia, there are no benefits of early treatment. In contrast to few other forms of cancer, hairy cell leukemia is relatively curable in all stages, translating to the fact that remission would not be any lesser if one adopted the wait and watch approach for treatment. In case the  [...]

November 12th, 2009 | Blood Cancer
Hairy Cell Leukemia : Detection And Likely Complications
Hairy Cell Leukemia : Detection And Likely Complications
Diagnosis & Tests: In case there are doubts about the presence of hairy cell leukemia then the doctor would be observant for the following three signs: Spleen enlargement. Lower count of all the types of blood cells. Presence of hairy cell leukemia in the blood. In order to look out for these indicators the doctor would carry out several tests and examinations that would comprise of: Physical Examination The doctor would palpate the ellipsoidal-shaped organ placed to the left side of the upper part of the abdomen to check whether there is any kind of enlargement. An enlargement in the spleen could lead to feeling full in the abdomen that could cause discomfort during eating. The doctor might additionally look out for any enlargement in the lymph nodes that could point to the presence  [...]

November 12th, 2009 | Blood Cancer
Hairy Cell Leukemia
Hairy Cell Leukemia
Hairy cell leukemia is an atypical, gradually progressing cancer of the blood wherein there is excessive production of the B cells or lymphocytes (kind of infection-combatant white blood cells) in the bone marrow. These surfeit B cells are anomalous and appear ‘hairy’ microscopically due to the fine protuberances or villi from their surface. Due to the surge in amounts of leukemia cells, there is lesser production of healthy white blood cells, red blood cells and platelets. Annually in the United States, nearly 600-800 individuals are detected with hairy cell leukemia. Hairy cell leukemia is observed to affect the male gender greater than the female, occurring mostly in the middle-age bracket or elderly individuals. Hairy cell leukemia is not known to affect kids and those in their teens. Doctors  [...]

November 11th, 2009 | Blood Cancer
Hairy Cell Leukemia Treatment With Cladribine- Probable Side Effects
Hairy Cell Leukemia Treatment With Cladribine- Probable Side Effects
Cladribine (Cladribine Novaplus, Leustatin) Cladribine is a cancer or antineoplastic medication for treating a form of blood cancer (Hairy Cell Leukemia) that hinders the spread of cancer cells, retarding their growth and proliferation in the body. Cladribine, however, has been additionally employed for other purposes. Likely Side effects of cladribine (Cladribine Novaplus, Leustatin) In case one is experiencing any of the below stated grave side effects, then it is vital to seek prompt medical assistance or get in touch with one’s doctor urgently. An allergic reaction characterised by shortened breath; feeling a restricted or closed sensation in the throat; breathing distress; the lips, face or tongue swelling up or appearance of hives. Lowered functioning of the bone marrow and blood  [...]

November 10th, 2009 | Blood Cancer